Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02037425 · ClinicalTrials.gov registry record · Phase 4
Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine
A Phase 4 study, sponsored by Cady, Roger, M.D..
- Completed
- Registry status
- Phase 4
- Development phase
- 44
- Enrollment target
NCT02037425 is a Phase 4 study that has completed, run by Cady, Roger, M.D.. The registered enrollment target is 44 participants.
The verdict
NCT02037425, a Phase 4 study, has completed, sponsored by Cady, Roger, M.D..
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 44 participants
- Enrollment target
Study Summary
To obtain a patient specific understanding of response to treatment with onabotulinumtoxinA by collecting and correlating pre and post treatment subject specific history, clinical outcomes, and histological changes.
Interventions
- DRUG onabotulinumtoxinA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2014-04 |
| Est. Completion | 2015-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02037425
The ClinicalTrials.gov registry entry for NCT02037425 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cady, Roger, M.D., which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which onabotulinumtoxinA is the first listed.
NCT02037425 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02037425 about?
NCT02037425 is a clinical study titled "Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine". To obtain a patient specific understanding of response to treatment with onabotulinumtoxinA by collecting and correlating pre and post treatment subject specific history, clinical outcomes, and histological changes.
What is the current status of trial NCT02037425?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 44 participants. The study started on 2014-04. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02037425?
The interventions under investigation include: onabotulinumtoxinA (DRUG).
Who is sponsoring clinical trial NCT02037425?
This trial is sponsored by Cady, Roger, M.D., which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.